2fjf
Structure of the G6 Fab, a phage derived VEGF binding Fab
|
OverviewOverview
In the quest to discover new research tools and to develop better agents, in the fight against cancer, two antibodies, G6 and B20-4, were isolated, from synthetic antibody phage libraries. Unlike the AVASTINtrade mark, antibody, a recently approved agent for the treatment of patients with, colorectal cancer, B20-4 and G6 bind and block both human and murine, vascular endothelial growth factor (VEGF). Here we have analyzed and, compared the binding epitopes on VEGF for these three antibodies using, alanine-scanning mutagenesis and structural analyses. The epitopes, recognized by both synthetic antibodies are conserved between human and, mouse VEGF, and they match closely to the receptor epitopes both, structurally and functionally. In contrast, the Avastin epitope overlaps, minimally with the receptor binding surface and centers around a residue, that is not conserved in mouse. Our structural and functional analyses, elucidate the cross-species reactivity of all three antibodies and, emphasize the potential advantages of antibody generation using phage, display as the resulting antibodies do not depend on sequence differences, across species and preferentially target natural protein-protein, interaction surfaces.
DiseaseDisease
Known disease associated with this structure: Kappa light chain deficiency OMIM:[147200]
About this StructureAbout this Structure
2FJF is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab., Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C, J Biol Chem. 2006 Mar 10;281(10):6625-31. Epub 2005 Dec 22. PMID:16373345
Page seeded by OCA on Mon Nov 12 22:06:13 2007